Merocarb (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This leads to weakened cell walls, osmotic instability and bacterial lysis. Its high affinity for multiple PBPs and resistance to most β‑lactamases give it activity against a wide range of pathogens.

The dosing regimen for Merocarb is individualized by the prescribing clinician based on infection type, severity, patient weight, renal function and local susceptibility patterns. Healthcare professionals determine the appropriate dose, infusion rate and treatment duration according to current clinical guidelines and patient‑specific factors.

Safety data for meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only when the potential maternal benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as the drug may be excreted in milk.

To request Merocarb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Merocarb (meropenem) offers a broader spectrum against resistant Gram‑negative organisms compared with imipenem/cilastatin, and it is less likely to cause seizures. Unlike ertapenem, meropenem retains activity against Pseudomonas aeruginosa and Acinetobacter spp. Choice of carbapenem depends on local resistance patterns, infection site and patient tolerance.

Merocarb should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture and extreme temperature fluctuations. Once reconstituted, use the preparation within the time frame recommended by the manufacturer and discard any unused portion.

Merocarb is supplied as a sterile intravenous solution. It is reconstituted with the appropriate diluent and administered by slow infusion, typically over 30 minutes, under aseptic conditions. The infusion rate and duration are set by the prescribing clinician according to the infection severity and patient renal function.

The most critical adverse events include seizure activity, especially in patients with renal impairment, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Clinicians should monitor neurological status, signs of allergic response and gastrointestinal symptoms throughout therapy.

Merocarb is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Patients with a history of severe allergic reactions to related drugs should avoid its use. Caution is also advised for patients with significant renal dysfunction unless dose adjustments are made.